Comparison of Bone Mineral Loss in Prostate Cancer Patients Who is Receiving GnRH Agonist and -Plus Anti-androgen Agent

AstraZeneca

Status: Completed

Conditions: GnRH Agonist Alone vs. GnRH Agonist Plus Anti-androgen Combination Treated Prostate Cancer Patients

Study type: Observational

Funder types: Industry

Identifiers

NCT01303692

NIS-OKR-CAS-2010/1

Details and patient eligibility

About

Comparison of bone mineral loss in prostate cancer patients who is receiving GnRH agonist and -plus anti-androgen agent

Full description

MC MD

Enrollment: 312 patients

Sex: Male

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Korean prostate cancer over 50 years old with pathological confirmation
• Patients receiving GnRH antagonist or GnRH agonist plus anti- androgen combination within 6 months since starting.
• Patients measured bone density level before starting to receive hormone therapies above.

Exclusion criteria

• Patients who are treated other anti-osteoporosis drugs and who are treated bisphosphate due to BMD T score below -3.0.
• Patients who are hard to be analysed by attach to other bone disease.
• Patients who are hard to be analysed by limitation of chart record according to investigators'discretion.

Trial design

312 participants in 2 patient groups

A

Description:

Total of 250 prostate cancer patients receiving GnRH agonist

B

Description:

Total of 250 prostate cancer patients receiving GnRH agonist plus anti-androgen agent